查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933360

全球大環內酯類抗生素市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察及未來預測（2026-2034）

Macrolide Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

大環內酯類抗生素市場成長因子

2025年全球大環內酯類抗生素市場規模達到61.6億美元，預計2026年將成長至63.7億美元，到2034年將達到88.3億美元，預測期內年複合成長率（CAGR）為4.17%。北美地區在2025年佔據47.39%的市場佔有率，這主要得益於該地區細菌感染的高發生率、先進的醫療基礎設施以及強大的研發投入。大環內酯類抗生素是一類透過與細菌核醣體的50S亞基結合來抑制細菌蛋白質合成的藥物。這些藥物，包括阿奇黴素、克拉黴素和紅黴素，用於治療嚴重的感染，特別是在兒童中，例如呼吸道感染、皮膚感染、性傳染病和彎曲桿菌感染。

市場上的主要公司，包括 Pfizer Inc.、Teva Pharmaceutical Industries Ltd.、Merck & Co., Inc.，正致力於擴大全球市場准入、推出仿製藥以及投資開發創新型大環內酯類藥物。

市場動態

驅動因素：全球細菌感染病例的增加是市場成長的主要驅動因素。呼吸道感染、性傳染感染（STI）和皮膚感染病例的增加推動大環內酯類藥物的需求。例如，根據世界衛生組織2024年7月的資料，15至49歲成年人中將新增8,240萬例淋病病例。此外，零售處方量也在上升，2023年美國每千人開出約105張處方，這推動大環內酯類藥物的使用。

限制因素：由於生產缺陷導致的頻繁產品召回會損害消費者信任和品牌聲譽，阻礙市場成長。例如，2025年2月，新加坡衛生科學局因無菌問題召回了500毫克克拉黴素粉劑；2023年12月，英國藥品和保健產品監管局（MHRA）也因醫療缺陷召回了克拉黴素片劑。

機會：新興市場日益重視本土藥物研發，帶來了巨大的機會。價格合理的本地化生產有助於緩解亞洲、非洲和拉丁美洲沉重的疾病負擔。例如，在BIRAC的支持下，印度於2024年11月推出了用於治療抗藥性社區獲得性細菌性肺炎的萘菲黴素（Miqnaf）。

挑戰：大環內酯類藥物的副作用（例如胃腸道不適、噁心和QT間期延長）是長期使用的障礙，尤其是紅黴素。這些副作用增加了密切監測的必要性，並限制了其在易感人群中的使用。

市場趨勢

持續的藥物研發和創新是關鍵趨勢。研究重點在於對抗抗生素抗藥性。例如，2024年7月，伊利諾大學研發 "大環內酯類抗生素" （macrolone），這是一種雙效抗生素，可同時靶向核醣體蛋白合成和DNA複製，使細菌難以產生抗藥性。這些進展塑造未來的市場策略，並有助於提高全球大環內酯類藥物的療效。

市場區隔分析

依產品劃分：阿奇黴素以其廣譜抗菌活性、長半衰期和極少的胃腸道副作用，佔據市場主導地位。克拉黴素也擁有較大的市場佔有率，尤其是在幽門螺旋桿菌感染的治療方面。紅黴素則受益於仿製藥的上市及其在兒科領域的應用。油黴素和其他大環內酯類抗生素預計將保持穩定成長。

依疾病區分：呼吸道感染是推動市場成長的主要因素，包括肺炎、鼻竇炎、咽炎和白喉。由於衣原體感染和淋病病例的增加，性傳染感染（STI）預計將會成長。皮膚感染的年複合成長率適中，主要受痤瘡和金黃色葡萄球菌感染的推動。

給藥途徑：口服製劑因其使用方便且易於取得而佔據主導地位，而注射製劑則用於需要快速起效的住院患者。可局部使用的外用製劑正穩定成長。

年齡組：兒科患者佔比最大，因為許多大環內酯類藥物已獲準用於兒科。成人用藥量也在上升，這得益於新的成人產品上市和監管部門的批准。

分銷通路：零售藥局和藥局佔最大佔有率，2022年美國共開立3,610萬張大環內酯類處方。由於其便利性、隱私性和成本優勢，線上藥局也在不斷發展。由於醫院藥房在醫療機構中被用作一線治療藥物，因此其市場佔有率仍然相當可觀。

區域展望

北美：受傳染病流行、積極的研發活動和資金投入的推動，到2025年，北美市場規模達到29.2億美元。美國憑藉仿製藥的上市和在對抗抗生素抗藥性方面的投資，在該地區處於領先地位。

歐洲：在廣譜抗生素需求不斷成長的推動下，歐洲佔據第二大市場。2019年至2021年，歐洲最後一道防線抗生素的消費量顯著增加。

亞太地區：由於醫療保健服務的可及性提高、預期壽命延長以及孟加拉國（2024年，用於對抗被忽視的熱帶病）預先批准使用氨曲霉素等藥物，預計亞太地區的年複合成長率將最高。

拉丁美洲、中東和非洲：由於細菌感染的流行以及與世界衛生組織倡議的合作（例如，Pfizer公司捐贈阿奇黴素用於對抗沙眼），預計成長將較為溫和。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區主要疾病流行情況（2025年）
  • 主要公司產品線分析
  • 關鍵產業趨勢：併購、業務合作等
  • 主要國家和地區的監管和償付情況

第5章 全球大環內酯類藥物市場抗生素市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 阿奇黴素
    • 克拉黴素
    • 奧利黴素
    • 紅黴素
    • 其他
  • 市場分析、洞察與預測：依疾病分類
    • 呼吸道感染
    • 皮膚感染
    • 性傳染感染（STI）
    • 其他
  • 市場分析、洞察與預測：依給藥途徑分類
    • 口服
    • 腸外給藥
    • 其他
  • 市場分析、洞察與預測：依年齡分類組別
    • 成人
    • 兒科
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美大環內酯類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲大環內酯類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區大環內酯類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲大環內酯類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲大環內酯類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Crescent Pharma Ltd.
    • Wellona Pharma
    • Zydus Group
    • Merck &Co., Inc.
    • Alkem
    • Azurity Pharmaceuticals, Inc.
    • Lupin
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI113847

Growth Factors of macrolide antibiotics Market

The global macrolide antibiotics market was valued at USD 6.16 billion in 2025 and is projected to grow to USD 6.37 billion in 2026, reaching USD 8.83 billion by 2034, exhibiting a CAGR of 4.17% during the forecast period. North America dominated the market in 2025 with a 47.39% share, supported by high prevalence of bacterial infections, advanced healthcare infrastructure, and strong R&D investments. Macrolides are a class of antibiotics that inhibit bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes. These drugs, including azithromycin, clarithromycin, and erythromycin, are used to treat respiratory tract infections, skin infections, sexually transmitted diseases, and serious infections such as Campylobacter infections, particularly in children.

Key players operating in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc., focusing on expanding global access, launching generics, and investing in innovative macrolide development.

Market Dynamics

Drivers: The increasing prevalence of bacterial infections worldwide is the main driver of market growth. Rising cases of respiratory infections, sexually transmitted infections (STIs), and skin infections boost demand for macrolides. For example, WHO data in July 2024 reported 82.4 million new gonorrhoeae infections among adults aged 15-49. Additionally, retail prescriptions are increasing, with approximately 105 prescriptions per 1,000 population in the U.S. in 2023, fueling macrolide usage.

Restraints: Frequent product recalls due to manufacturing defects hamper market growth by reducing consumer trust and brand reputation. For instance, in February 2025, the Health Sciences Authority of Singapore recalled clarithromycin 500 mg powder due to sterility issues, while the U.K. MHRA recalled clarithromycin tablets in December 2023 due to medical defects.

Opportunities: The rising focus on indigenous drug development in emerging markets presents substantial opportunities. Affordable local production addresses high disease burden in Asia, Africa, and Latin America. For example, India launched Nafithromycin (Miqnaf) in November 2024 targeting drug-resistant community-acquired bacterial pneumonia, supported by BIRAC.

Challenges: Adverse effects associated with macrolides, such as gastrointestinal upset, nausea, and QT interval prolongation, pose challenges to long-term adoption, particularly in erythromycin use. These effects increase the need for careful monitoring and limit usage in vulnerable populations.

Market Trends

Ongoing drug development and innovation are key trends. Research is focused on combating antibiotic resistance. For instance, in July 2024, the University of Illinois developed macrolones, dual-action antibiotics targeting both ribosomal protein synthesis and DNA replication, making bacterial resistance less likely. Such advancements are shaping future market strategies and improving the effectiveness of macrolide therapy globally.

Segmentation Analysis

By Product: Azithromycin dominates due to broad-spectrum activity, longer half-life, and fewer gastrointestinal side effects. Clarithromycin holds a substantial share, particularly in H. pylori treatment, while erythromycin benefits from generic launches and pediatric applications. Oleandomycin and other macrolides are expected to grow steadily.

By Disease Indication: Respiratory tract infections lead the market, including pneumonia, sinusitis, pharyngitis, and diphtheria. STIs are projected to grow due to rising cases of chlamydia and gonorrhea. Skin infections show moderate CAGR, fueled by acne and Staphylococcus aureus-related infections.

By Route of Administration: The oral segment dominates due to ease of use and availability, while parenteral formulations cater to hospitalized patients needing rapid action. Topical formulations are growing steadily due to site-specific applications.

By Age Group: Pediatric patients capture the dominant share, as many macrolides are approved for children. Adult usage is growing with new product launches and regulatory approvals.

By Distribution Channel: Retail pharmacies & drug stores hold the largest share, accounting for 36.1 million macrolide prescriptions in the U.S. in 2022. Online pharmacies are growing due to convenience, privacy, and cost savings. Hospital pharmacies maintain a considerable share due to first-line treatment usage in healthcare settings.

Regional Outlook

North America: Market size reached USD 2.92 billion in 2025, driven by infection prevalence, robust R&D, and funding initiatives. The U.S. leads the region due to generic launches and investments to tackle antibiotic resistance.

Europe: Holds the second-largest share, supported by increased demand for broad-spectrum antibiotics. Consumption of last-line antibiotics increased substantially between 2019-2021.

Asia Pacific: Projected to grow at the highest CAGR, fueled by better healthcare access, increasing life expectancy, and prequalification of drugs like azithromycin in Bangladesh (2024) for neglected tropical diseases.

Latin America & Middle East & Africa: Moderate growth is expected due to bacterial infections and collaborations with WHO initiatives, such as Pfizer's donation of Zithromax to control trachoma.

Competitive Landscape

The market is semi-consolidated, with key players including Pfizer Inc., Teva, Merck & Co., Lupin, Sun Pharmaceutical, Zydus Group, and others. Strategies include generic launches, collaborations, and R&D investment to maintain competitive positioning.

Conclusion

The global macrolide antibiotics market is projected to grow from USD 6.16 billion in 2025 to USD 6.37 billion in 2026, reaching USD 8.83 billion by 2034 at a CAGR of 4.17%. Growth is driven by rising bacterial infections, increasing prescriptions, and innovations addressing antimicrobial resistance. Challenges like adverse drug effects and product recalls persist, but opportunities in emerging markets and drug development strategies make the outlook favorable for both established and emerging players over the forecast period.

Segmentation By Product

  • Azithromycin
  • Clarithromycin
  • Oleandomycin
  • Erythromycin
  • Others

By Disease Indication

  • Respiratory Infections
  • Skin Infections
  • Sexually Transmitted Diseases (STIs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Adults
  • Pediatrics

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Azithromycin
    • 5.1.2. Clarithromycin
    • 5.1.3. Oleandomycin
    • 5.1.4. Erythromycin
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Respiratory Infections
    • 5.2.2. Skin Infections
    • 5.2.3. Sexually Transmitted Diseases (STIs)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Adults
    • 5.4.2. Pediatrics
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Azithromycin
    • 6.1.2. Clarithromycin
    • 6.1.3. Oleandomycin
    • 6.1.4. Erythromycin
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Respiratory Infections
    • 6.2.2. Skin Infections
    • 6.2.3. Sexually Transmitted Diseases (STIs)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Adults
    • 6.4.2. Pediatrics
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Azithromycin
    • 7.1.2. Clarithromycin
    • 7.1.3. Oleandomycin
    • 7.1.4. Erythromycin
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Respiratory Infections
    • 7.2.2. Skin Infections
    • 7.2.3. Sexually Transmitted Diseases (STIs)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Adults
    • 7.4.2. Pediatrics
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Azithromycin
    • 8.1.2. Clarithromycin
    • 8.1.3. Oleandomycin
    • 8.1.4. Erythromycin
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Respiratory Infections
    • 8.2.2. Skin Infections
    • 8.2.3. Sexually Transmitted Diseases (STIs)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Adults
    • 8.4.2. Pediatrics
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Azithromycin
    • 9.1.2. Clarithromycin
    • 9.1.3. Oleandomycin
    • 9.1.4. Erythromycin
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Respiratory Infections
    • 9.2.2. Skin Infections
    • 9.2.3. Sexually Transmitted Diseases (STIs)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Adults
    • 9.4.2. Pediatrics
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Azithromycin
    • 10.1.2. Clarithromycin
    • 10.1.3. Oleandomycin
    • 10.1.4. Erythromycin
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Respiratory Infections
    • 10.2.2. Skin Infections
    • 10.2.3. Sexually Transmitted Diseases (STIs)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Adults
    • 10.4.2. Pediatrics
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Crescent Pharma Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wellona Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Group
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Alkem
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Azurity Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Lupin
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 5: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 9: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table10: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 11: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 15: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 16: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 17: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 21: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 22: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 27: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 33: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 35: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Macrolide Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Macrolide Antibiotics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Macrolide Antibiotics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 6: Global Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Macrolide Antibiotics Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 10: North America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 11: North America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 12: North America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 13: North America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 14: North America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 15: North America Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 16: North America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Macrolide Antibiotics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Macrolide Antibiotics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 22: Europe Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 23: Europe Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 24: Europe Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Europe Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 26: Europe Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 27: Europe Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 28: Europe Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 35: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 36: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 37: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 38: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 39: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 40: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 46: Latin America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 47: Latin America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 48: Latin America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 49: Latin America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 50: Latin America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 51: Latin America Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 52: Latin America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 59: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 60: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 61: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 62: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 63: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 64: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Macrolide Antibiotics Market Share (%), By Company, 2025